Abstract
Experimental data suggest that glioblastoma cells expressing the stem cell marker CD133 play a major role in radiochemoresistance and tumor aggressiveness. To date, however, there is no clinical evidence that the fraction of CD133-positive cells in glioblastoma that recurs after radiochemotherapy may be relevant for prognosis.
| Lingua originale | Inglese |
|---|---|
| pagine (da-a) | 162-174 |
| Numero di pagine | 13 |
| Rivista | Cancer |
| Volume | 117 |
| DOI | |
| Stato di pubblicazione | Pubblicato - 2011 |
Keywords
- Adult
- Aged
- Antigens, CD
- Brain Neoplasms
- Female
- Glioblastoma
- Glycoproteins
- Humans
- Male
- Middle Aged
- Neoplastic Stem Cells
- Neural Stem Cells
- Peptides
- Prognosis
- Recurrence
- Tumor Markers, Biological
Fingerprint
Entra nei temi di ricerca di 'Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis'. Insieme formano una fingerprint unica.Cita questo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver